Financial Data and Key Metrics Changes - For the full year 2025, sales increased by 8% on a reported basis and over 6% organically, while adjusted operating income grew by 13% [4][25] - Adjusted EPS increased by 21%, reflecting higher sales, improved profitability, and effective capital management [4][25] - In the fourth quarter, sales totaled $472 million, reflecting 5% growth on a reported basis and 2% growth on an organic basis [24] Business Line Data and Key Metrics Changes - Cardio and vascular sales increased by 11% to $284 million in Q4 2025, driven by acquisitions and strong demand in neurovascular [26] - Cardiac rhythm management and neuromodulation sales decreased by 2% to $167 million in Q4 2025, primarily due to lower demand from select emerging customers [27] Market Data and Key Metrics Changes - The medical device market remains attractive, with expected growth in mid-single digits for cardiovascular, neuromodulation, and cardiac rhythm management markets [10][11] - The company expects its underlying business to grow 4%-6% in line with the market, excluding the impact of three new products [6][35] Company Strategy and Development Direction - The company focuses on investing in differentiated capabilities and partnering with customers early in the design and development stage of new products [11][12] - A robust and diversified product development pipeline is oriented towards high-growth markets, with expectations of returning to above-market organic growth in 2027 [10][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to return to 200 basis points above-market organic growth in 2027, despite temporary headwinds in 2026 [7][39] - The company is maintaining a disciplined approach to capital management while investing in growth initiatives [21][39] Other Important Information - The company repurchased $50 million of common stock in Q4 2025 and announced an accelerated share repurchase program for an additional $50 million [4][5] - Adjusted effective tax rate for the full year was 17.2%, down from 18.3% in the prior year, reflecting tax benefits from R&D investment [30] Q&A Session Summary Question: Guidance on top line and the decision to lower the high end of the preliminary range - Management clarified that the adjustment was more about rounding than specific dynamics in January [42] Question: Return to operating income growth above sales growth in 2027 - Management expects margin expansion in the second half of 2026, with a return to above-market growth in 2027 [44] Question: Contribution from new products and their performance - Management indicated that the portfolio of products is expected to grow 15%-20% over the next 3-5 years, with good visibility on launch dates and expected revenues [47] Question: DSO increase and its implications - Management explained that the increase in DSO was due to limiting accounts receivable factoring to maintain financial flexibility [54] Question: Operating margin and its year-over-year decline - Management noted that fixed costs are more challenging to absorb with lower sales numbers, particularly in Q1 [60] Question: Visibility on customer forecasts and market dynamics - Management confirmed that discussions with customers align with their projections, indicating confidence in the guidance provided [66]

Integer (NYSE:ITGR) Q4 2025 Earnings call February 19, 2026 09:00 AM ET Speaker7Good morning, and thank you for standing by. Welcome to Energous, excuse me, Integer Holdings Corporation's fourth quarter 2025 earnings call. My name is Audra, and I will be your conference operator today. At this time, all participants are in a listen-only mode. After the prepared remarks, there will be a question-and-answer session. Please note this call is being recorded. I would now like to turn the conference over to Krist ...

Integer Holdings Corporation (ITGR) Fourth Quarter 2025 Earnings Conference Call February 19, 2026 Presenters and Agenda Today's agenda: Kristen Stewart, CFA Director, Investor Relations CONFIDENTIAL | February 19, 2026 | 2 ITGR: 4Q25 Earnings Conference Call Payman Khales President, Chief Executive Officer Diron Smith Executive Vice President, Chief Financial Officer • Opening Remarks • Strategy Update • Financial Results • Financial Outlook • Wrap-up • Q&A Presentation of Financial Information & Forward-L ...

Financial Performance - Integer Holdings Corporation achieved 8% sales growth and 21% adjusted EPS growth for the full year 2025 compared to 2024[1][4] - In Q4 2025, Cardio & Vascular sales increased 11% to $284 million, while full year sales rose 17% to $1.107 billion[5][21] - Adjusted operating income for 2025 increased by 13% to $321 million, with adjusted net income rising 23% to $226 million[6][19] - Integer Holdings Corporation reported Q4 2025 sales of $472.06 million, a 5.7% increase from $449.50 million in Q4 2024[37] - For the full year 2025, sales reached $1.85 billion, up 8.0% from $1.72 billion in 2024[37] - Gross profit for Q4 2025 was $124,756 thousand, up from $116,796 thousand in Q4 2024, representing a 8.4% increase[38] - Operating income for the year ended December 31, 2025, was $221,264 thousand, compared to $208,238 thousand in 2024, reflecting a 6.4% growth[38] - Net income for 2025 was $102,808 thousand, down from $119,896 thousand in 2024, indicating a decrease of 14.3%[39] - Adjusted net income (Non-GAAP) for 2025 was $272,526 thousand, compared to $224,747 thousand in 2024, reflecting a 21.2% increase[42] Sales and Market Trends - The company expects 2026 sales guidance in the range of $1.826 billion to $1.876 billion, reflecting a slight decline of 1% to an increase of 1% from 2025[9] - Adjusted EPS for 2026 is projected to be between $6.29 and $6.78, indicating a decrease of 2% to an increase of 6% compared to 2025[9] - Cardiac Rhythm Management & Neuromodulation sales decreased 2% to $167 million in Q4 2025, while full year sales increased by 1% to $669 million[13][21] - Other Markets sales fell 13% to $21 million in Q4 2025, with a full year decline of 27% to $78 million[13][21] - Integer anticipates returning to 200 basis points above-market organic sales growth in 2027[4] - The company experienced a total sales growth of 5.0% in Q4 2025 compared to Q4 2024, with organic sales change of 2.0% after adjusting for foreign currency and acquisitions[58] - Cardio & Vascular segment sales grew by 11.3% in Q4 2025, while the Cardiac Rhythm Management & Neuromodulation segment saw a decline of 1.9%[58] Debt and Financial Position - Total debt increased by $195 million to $1.185 billion, resulting in a leverage ratio of 3.0 times adjusted EBITDA as of December 31, 2025[6] - Integer's net total debt was $1.19 billion as of December 31, 2025, compared to $990.15 million in 2024, indicating a 20.1% increase[36] - Total debt increased to $1,185,179,000 as of December 31, 2025, from $990,153,000 in 2024, resulting in a net total debt of $1,190,123,000, up from $954,451,000[61] Shareholder Activities - Integer plans to repurchase approximately $50 million of its common stock as part of an accelerated share repurchase program[8] - The company plans to engage in share repurchase activities, including an Accelerated Share Repurchase (ASR) program[31] Operational Efficiency and Costs - The company incurred $46,681 thousand in debt conversion inducement expense in 2025, which was not present in 2024[39] - The company incurred restructuring and restructuring-related charges of $3,767,000 in Q4 2025, compared to $1,517,000 in Q4 2024, indicating increased costs associated with realignment efforts[54] - The implementation of a new global ERP solution incurred costs of $1,651,000 in 2025, indicating a significant investment in operational efficiency[54] - The company recorded leadership transition costs of $2,400,000 in Q4 2025 and $4,100,000 for the year, reflecting ongoing strategic adjustments[50] Cash Flow and Assets - Cash flows from operating activities for 2025 totaled $196,148 thousand, slightly down from $205,205 thousand in 2024[40] - The company’s total assets increased to $3.41 billion in 2025, compared to $3.08 billion in 2024, reflecting a growth of 10.8%[36] - Current assets rose to $770.10 million in 2025, up from $671.12 million in 2024, marking a 14.8% increase[36] - Integer's cash and cash equivalents decreased to $17.16 million in 2025 from $46.54 million in 2024, a decline of 63.2%[36] - Cash and cash equivalents at the end of 2025 were $17,161 thousand, a decrease from $46,543 thousand at the end of 2024[40] Future Outlook - Adjusted EBITDA for the year is expected to reflect continued growth, supporting the company's strategy to enhance shareholder value[31] - The company anticipates a return to above-market organic sales growth in 2027, driven by new product developments and market expansions[31]

~ Delivered 8% sales growth and 21% adjusted EPS growth in full year 2025 ~ ~ 2026 Outlook maintains midpoint of sales growth and high end of adjusted EPS growth from October outlook ~~ Continue to expect 200bps above-market organic sales growth in 2027 ~ PLANO, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading contract development and manufacturing organization, today announced results for the three and twelve months ended December 31, 2025. Unless otherwise state ...

Philadelphia, Pennsylvania--(Newsfile Corp. - February 17, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Integer Holdings, Corp. (NYSE: ITGR). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.If you purchased Integer Holdings, Corp. (NYSE: ITGR), shares prior to July 25, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a c ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Integer Holdings Corporation (NYSE: ITGR) between July 25, 2024, and October 22, 2025, of the lead plaintiff deadline on February 9, 2026, for a class action lawsuit related to alleged misleading statements by the company [1]. Group 1: Class Action Details - Investors who purchased Integer common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by February 9, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Allegations Against Integer Holdings - The lawsuit claims that Integer made materially false and misleading statements regarding its competitive position in the electrophysiology (EP) manufacturing market [5]. - It is alleged that Integer overstated its visibility into customer demand while experiencing a decline in sales for two of its EP devices [5]. - The company mischaracterized its EP devices as long-term growth drivers for its cardio and vascular (C&V) segment, leading to misleading positive statements about its business and operations [5].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) for allegedly misleading investors regarding its competitive position and sales performance in the EP manufacturing market [6]. Allegation Details - The complaint claims that the defendants failed to disclose that the company materially overstated its competitive position within the growing EP manufacturing market [3]. - It is alleged that despite the company's claims of strong visibility into customer demand, it was experiencing a sustained deterioration in sales related to two of its EP devices [3]. - The company mischaracterized its EP devices as a long-term growth driver for its C&V segment, leading to materially false and misleading statements about its business and prospects [3]. Next Steps - Investors who purchased or acquired Integer shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4]. - There is no cost or obligation for investors to inquire about the lawsuit [4]. - Investors have until February 9, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Integer Holdings Corporation (NYSE: ITGR) during the specified class period of the upcoming lead plaintiff deadline on February 9, 2026, for a class action lawsuit related to alleged misleading statements by the company [1]. Group 1: Class Action Details - Investors who bought Integer common stock between July 25, 2024, and October 22, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm or visiting their website [3][6]. - The deadline to move the Court to serve as lead plaintiff is February 9, 2026, which is crucial for those wishing to represent other class members [3]. Group 2: Allegations Against Integer Holdings - The lawsuit claims that Integer Holdings made materially false and misleading statements regarding its competitive position in the electrophysiology (EP) manufacturing market [5]. - It is alleged that despite claims of strong customer demand visibility, Integer was experiencing a decline in sales for two of its EP devices, contradicting its portrayal of these devices as long-term growth drivers for its cardio and vascular segment [5]. - The lawsuit asserts that the positive statements made by the defendants about Integer's business and prospects were materially false and misleading, leading to investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has been recognized for securing significant settlements for investors, including over $438 million in 2019 alone, and has consistently ranked highly in securities class action settlements since 2013 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Integer Holdings Corporation during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Integer common stock between July 25, 2024, and October 22, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Integer Holdings - The lawsuit alleges that Integer Holdings made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market [5]. - It is claimed that Integer overstated its visibility into customer demand while experiencing a decline in sales for two of its electrophysiology devices [5]. - The lawsuit asserts that Integer mischaracterized its electrophysiology devices as long-term growth drivers for its cardio and vascular segment, leading to misleading positive statements about its business and operations [5].